FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 213 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR “The power of science”: HPV vaccine proven to dramatically reduce cervical... November 3, 2021 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 Enhancements to NCI’s SEER Program Creating New Research Opportunities August 23, 2018 Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... June 30, 2021 Load more HOT NEWS Open Enrollment for 2022 Affordable Care Act Plans is Here! FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... Cure Probability Models for Evaluation of Patients with a Previous Cancer...
